Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Novel Oral KRAS G12D Inhibitor Receives FDA Fast Track Designation in Advanced PDAC

Results from a phase 1/2a trial supported the designation for VS-7375 in those with PDAC harboring a KRAS G12D mutation.

FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer

Verastem Oncology's VS-7375 receives FDA fast track designation, offering hope for targeted treatment in KRAS G12D-mutated pancreatic cancer.

VS-7375 oral medication on FDA fast track for pancreatic cancer

The experimental oral medication VS-7375 has been granted fast track designation for advanced pancreatic cancer in the U.S. The Food and Drug Administration (FDA) gives this designation to help speed the development of experimental therapies that have the potential to fill unmet medical needs in the care of serious diseases. Verastem Oncology is developing VS-7375 alongside Genfleet Therapeutics. “Given the encouraging initial safety and efficac…